• Explore /
  • Poster
  • / Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.

Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.

Abstract Video & Slides Poster

Authors

null

Eric Raymond

Centre Hospitalier Paris Saint-Joseph, Paris, France;

Eric Raymond , Richard Hubner , Evgeny Gotovkin , Lucjan Wyrwicz , Eric Van Cutsem , Paula Jimenez-Fonseca , Roberto Pazo-Cid , Jianming Xu , Ken Kato , Aiyang Tao , Lei Wang , Yanyan Peng , Liyun Li , Harry H. Yoon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03783442

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 340)

DOI

10.1200/JCO.2023.41.4_suppl.340

Abstract #

340

Poster Bd #

E1

Abstract Disclosures

Similar Posters

First Author: Kuaile Zhao

First Author: Jian-Ming Xu

First Author: Hendrik-Tobias Arkenau

First Author: Marcia Cruz-Correa